Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

Literature DB >> 21695064

THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

Chris Kenyon¹, Nicci Wearne, Rosie Burton, Graeme Meintjes.

Abstract

Entities: Chemical Disease Gene Species

Year: 2011 PMID： 21695064 PMCID： PMC3118283 DOI： 10.4102/sajhivmed.v12i1.214

Source DB: PubMed Journal: South Afr J HIV Med ISSN： 1608-9693 Impact factor: 2.744

× No keyword cloud information.

17 in total

1. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Authors: Joel E Gallant; Michelle A Parish; Jeanne C Keruly; Richard D Moore
Journal: Clin Infect Dis Date: 2005-03-17 Impact factor: 9.079

Review 2. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Authors: Ryan D Cooper; Natasha Wiebe; Nathaniel Smith; Philip Keiser; Saraladevi Naicker; Marcello Tonelli
Journal: Clin Infect Dis Date: 2010-09-01 Impact factor: 9.079

3. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.

Authors: A Winston; J Amin; Pwg Mallon; D Marriott; A Carr; D A Cooper; S Emery
Journal: HIV Med Date: 2006-03 Impact factor: 3.180

Review 4. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Authors: Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden
Journal: Clin Infect Dis Date: 2005-12-08 Impact factor: 9.079

5. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Authors: Robert T Schooley; Peter Ruane; Robert A Myers; Gildon Beall; Harry Lampiris; Daniel Berger; Shan-Shan Chen; Michael D Miller; Erica Isaacson; Andrew K Cheng
Journal: AIDS Date: 2002-06-14 Impact factor: 4.177

6. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.

Authors: Pablo Labarga; Pablo Barreiro; Luz Martin-Carbonero; Sonia Rodriguez-Novoa; Carmen Solera; Jose Medrano; Pablo Rivas; Marta Albalater; Francisco Blanco; Victoria Moreno; Eugenia Vispo; Vincent Soriano
Journal: AIDS Date: 2009-03-27 Impact factor: 4.177

7. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity.

Authors: Sven N Hobbie; Subramanian Akshay; Sarath K Kalapala; Christian M Bruell; Dmitry Shcherbakov; Erik C Böttger
Journal: Proc Natl Acad Sci U S A Date: 2008-12-22 Impact factor: 11.205

8. Tenofovir-induced kidney injury.

Authors: Michael D Gitman; David Hirschwerk; Cindy H Baskin; Pravin C Singhal
Journal: Expert Opin Drug Saf Date: 2007-03 Impact factor: 4.250

9. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

Authors: A M Galløe; N Graudal; H R Christensen; J P Kampmann
Journal: Eur J Clin Pharmacol Date: 1995 Impact factor: 2.953

10. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney
Journal: AIDS Date: 2007-06-19 Impact factor: 4.177

11 in total

1. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.

Authors: Hyejeong Hong; David W Dowdy; Kelly E Dooley; Howard W Francis; Chakra Budhathoki; Hae-Ra Han; Jason E Farley
Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079

2. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.

Authors: Hyejeong Hong; Kelly E Dooley; Laura E Starbird; Howard W Francis; Jason E Farley
Journal: Arch Toxicol Date: 2019-04-08 Impact factor: 5.153

Review 3. Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors: Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal: Expert Opin Drug Saf Date: 2019-12-06 Impact factor: 4.250

4. Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).

Authors: Richard Kaplan; Judy Caldwell; Keren Middelkoop; Linda-Gail Bekker; Robin Wood
Journal: J Acquir Immune Defic Syndr Date: 2014-08-15 Impact factor: 3.731